☆ 4.8 Editorial Material

Drug Policy for an Aging Population - The European Medicines Agency's Geriatric Medicines Strategy

NEW ENGLAND JOURNAL OF MEDICINE (2012)

期刊

NEW ENGLAND JOURNAL OF MEDICINE

卷 367, 期 21, 页码 1972-1974

出版社

MASSACHUSETTS MEDICAL SOC

DOI: 10.1056/NEJMp1209034

关键词

-

类别

Medicine, General & Internal

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Pharmacology & Pharmacy

Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making

Elisabeth Bakker, Kelly Plueschke, Carla J. Jonker, Xavier Kurz, Viktoriia Starokozhko, Peter G. M. Mol

Summary: Real-world data/evidence (RWD/RWE) can provide insightful information on medicines' clinical effects and guide regulatory decisions. However, further evaluation is needed to use RWD/RWE to demonstrate the efficacy of medicines. This study characterized RWD/RWE presented by applicants and analyzed its contribution to regulatory decisions on the benefit-risk profile of medicines. Common limitations of submitted RWD/RWE included missing data, lack of representativeness, and bias risks.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Medicine, General & Internal

Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations

Valentina Vignali, Philip A. Hines, Ana Gloria Cruz, Barbara Zietek, Ralf Herold

Summary: In the field of medicine development, it is crucial to keep up with the rapid progress in science and technology to translate them into benefits for society. Using horizon scanning, the European Medicines Agency collaborates with WHO and DG JRC to identify early signals of relevant innovation and technological trends in medicinal products. This helps inform policy-makers of new trends and improve preparedness in responding to them.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Assessing Medicines for Use in the Geriatric Population

Francesca Cerreta, Katarina Vucic, Andrea Laslop

Summary: The aging processes affect the body's response to medications and elderly patients are underrepresented in clinical trials. Evidence-based prescribing guidelines may result in inappropriate prescriptions, increasing the risk of drug interactions and adverse reactions. Clear information and proper consideration of older patients are necessary.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Behavioral Sciences

European space agency's hibernation (torpor) strategy for deep space missions: Linking biology to engineering

Alexander Chouker, Thu Jennifer Ngo-Anh, Robin Biesbroek, Gerhard Heldmaier, Marc Heppener, Juergen Bereiter-Hahn

Summary: Long-duration space missions to Mars will create extreme physical and psychological stress on the crew, as well as logistical and technical challenges. ESA's study has shown that biological hibernation can reduce crew metabolism and stress, but will require monitoring and AI assistance.

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2021)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population

Diana A. van Riet-Nales, Bart van den Bemt, David van Bodegom, Francesca Cerreta, Brian Dooley, Doris Eggenschwyler, Blanka Hirschlerova, Paul A. F. Jansen, Fatma Karapinar-Carkit, Abigail Moran, Jan Span, Sven Stegemann, Katarina Sundberg

Summary: This article discusses the needs and issues of older people in medication, and introduces the reflection paper published by the European Medicines Agency, which aims to help the pharmaceutical industry to better consider the needs of older people.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

The challenges of access to innovative medicines with limited evidence in the European Union

Antonio Vallano, Caridad Pontes, Antonia Agusti

Summary: The European Medicines Agency (EMA) has accelerated procedures and relaxed authorization requirements to provide access to innovative medicines for diseases with unmet medical needs. However, this has led to increased uncertainty about the efficacy and safety of these medicines, which has implications for clinical practice and pricing negotiations. Balancing timely access to new treatments with evidence-based decision-making and fair pricing is crucial but challenging. Rating: 7/10.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Dermatology

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Andreas Wollenberg, Jacob P. Thyssen, Thomas Bieber, Gary Chan, Urs Kerkmann

Summary: The PRAC of the EMA has reevaluated the benefit-risk balance of oral JAKi and recommended their use only if no suitable alternatives are available. They should be used with caution in patients with certain risk factors, and the European Commission has made a final decision in March 2023.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Outpatient fluoroquinolone use in relation to European Medicines Agency's recommendation: An Estonian nationwide drug utilization study

Katrin Kurvits, Maia Uuskula, Helve Vestman, Ott Laius

Summary: This study aimed to investigate the changes in prescribing of fluoroquinolones after the recommendation by EMA in October 2018. The results showed a decline in the number of prescriptions, but a significant proportion of users still had risk factors for tendon injury and serious cardiac disorders.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Access and use of WHO essential medicines in Italy

Alessandro Petrella, Filomena Fortinguerra, Agnese Cangini, Andrea Pierantozzi, Francesco Trotta

Summary: This study analyzed the availability and use of essential medicines in Italy based on the WHO Essential Medicines List. It found a high coverage and reimbursement rate for essential medicines in Italy, indicating their importance in healthcare policy choices. The study also highlighted the need for more frequent updates and easier access to information on rejected medicines.

FRONTIERS IN PUBLIC HEALTH (2023)

添加到收藏夹

Article Political Science

A widening authority-legitimacy gap in EU regulatory governance? An experimental study of the European Medicines Agency's legitimacy in health security regulation

Dovile Rimkute, Honorata Mazepus

Summary: Agencification in the EU extends the authority of European regulatory state to new policy domains traditionally handled by national institutions. This study examines the legitimacy of EU agencies, particularly the European Medicines Agency (EMA) in authorizing vaccines for cross-border health security risks. The findings suggest that the EMA is perceived as highly legitimate, and disapproval from national-level politicians and citizens does not undermine its epistemic authority in the eyes of local decision-makers.

JOURNAL OF EUROPEAN PUBLIC POLICY (2023)

添加到收藏夹

Article Medicine, General & Internal

Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment Reports

Maximilian Siebert, Jeanne Gaba, Alain Renault, Bruno Laviolle, Clara Locher, David Moher, Florian Naudet

Summary: This article introduces a study that aims to assess the inferential reproducibility of main trials assessed by the European Medicines Agency. The results show that most of the main studies used in European Public Assessment Reports lack transparency and their results are not reproducible for external researchers. However, re-analyses of the few trials with available data showed very good inferential reproducibility.

BMC MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Access to medicines for rare diseases: A European regulatory roadmap for academia

Noa Rosenberg, Sibren van den Berg, Nina N. Stolwijk, Bart A. W. Jacobs, Hendrika C. Post, Anna M. G. Pasmooij, Saco J. de Visser, Carla E. M. Hollak

Summary: This paper provides an easily applicable roadmap for academic researchers to make rare disease medicines available for patients. It emphasizes the importance of interaction with regulators and highlights alternative routes for timely access to medicines. Aligning academic studies with regulatory and reimbursement requirements is crucial for improving access to rare disease medicines.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Review Pediatrics

Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process

Angeliki Siapkara, Claudio Fracasso, Gunter F. Egger, Carmelo Rizzari, Cristina Seren Trasorras, Dimitrios Athanasiou, Mark A. Turner

Summary: In order to improve the conduct of clinical trials in babies, children and young people, a working group was formed by the European Network of Paediatric Research at the European Medicines Agency. The key recommendations of the group include starting early, identifying clinical need, listening to stakeholders, estimating resources needed, and presenting information in a structured way. Well-prepared trials are likely to require fewer changes, be completed in a shorter time frame and achieve expected objectives.

ARCHIVES OF DISEASE IN CHILDHOOD (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Patient-reported, observer-reported and performance outcomes in qualification procedures at the European Medicines Agency 2013-2018

Marcio Silva, Jane Moseley, Thorsten Vetter, Jan Regnstrom, Maria Tome, Stiina Aarum, Francesca Cerreta, Elmer Schabel, Spiros Vamvakas

Summary: This study describes the characteristics of applicant, tool, outcomes, regulatory responses, and general learnings from European Medicines Agency (EMA) Qualification Procedures on patient-reported outcomes (PROs), observer-reported outcomes (ObsROs), and performance outcomes (PerfOs) finalized between January 2013 and December 2018. The study found that there were 17 qualification programs for PROs, 6 for ObsRO tools, and 11 for PerfO tools submitted to EMA, with gastroenterology and neurology being the most frequent therapeutic areas. The regulators showed a high level of partial agreement with the approaches of the applicants and provided constructive input.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

European regulatory strategy for supporting childhood cancer therapy developments

Dominik Karres, Giovanni Lesa, Franca Ligas, Sylvie Benchetrit, Sara Galluzzo, Karen Van Malderen, Jaroslav Sterba, Maaike van Dartel, Marleen Renard, Peter Sisovsky, Siri Wang, Koen Norga

Summary: Regulatory decisions on paediatric investigation plans (PIPs) are crucial for providing effective and safe medicines for children with unmet medical needs, particularly in the field of paediatric oncology. Coordinating with stakeholders is essential for prioritizing and accelerating drug development in this challenging area.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations

Giovanni Tafuri, Ines Lucas, Steve Estevao, Jane Moseley, Anne d'Andon, Hannah Bruehl, Elangovan Gajraj, Sonia Garcia, Niklas Hedberg, Marco Massari, Andrea Molina, Merce Obach, Leeza Osipenko, Frank Petavy, Marco Petschulies, Caridad Pontes, Pierluigi Russo, Anja Schiel, Marc Van de Casteele, Eva-Maria Zebedin-Brandl, Guido Rasi, Spiros Vamvakas

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

Hans-Georg Eichler, Brigitte Bloechl-Daum, Karl Broich, Paul Alexander Kyrle, Jillian Oderkirk, Guido Rasi, Rui Santos Ivo, Ad Schuurman, Thomas Senderovitz, Luke Slawomirski, Martin Wenzl, Valerie Paris

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Added therapeutic benefit and drug licensing

Hans-Georg Eichler, Harald Enzmann, Guido Rasi

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation

Hans-Georg Eichler, Franz Koenig, Peter Arlett, Harald Enzmann, Anthony Humphreys, Frank Petavy, Brigitte Schwarzer-Daum, Bruno Sepodes, Spiros Vamvakas, Guido Rasi

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Pharmacovigilance 2030 Invited Commentary for the January 2020 Futures Edition of Clinical Pharmacology and Therapeutics

Peter Arlett, Sabine Straus, Guido Rasi

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Big Data - How to Realize the Promise

Alison Cave, Nikolai C. Brun, Fergus Sweeney, Guido Rasi, Thomas Senderovitz, Ada Georgescu, Aldana Rosso, Alexandra Pacurariu, Antti H. Hyvarinen, Cesar Hernandez Garcia, Didier Meulendijks, Dieter Deforce, Gavril Flores, Gianmario Candore, Hans Ovelgonne, Katherine Donegan, Kevin Horan, Luis Pinheiro, Marek Lehmann, Marjon Pasmooij, Mark Goldammer, Martin Nyeland, Mateja Sajovic, Miguel Angel Macia, Nikolai Brun, Panagiotis Telonis, Paolo Alcini, Per Fuglerud, Renate Konig, Roxana Dondera, Roxana Stroe, Vesa Kiviniemi, Zsuzsanna Cserjes Szabone, Zsuzsanna Szabone Cserjes

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

Clinical trial publications: A sufficient basis for healthcare decisions?

Hans-Georg Eichler, Guido Rasi

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?

Hans-Georg Eichler, Marco Cavaleri, Harald Enzmann, Francesca Scotti, Bruno Sepodes, Fergus Sweeney, Spiros Vamvakas, Guido Rasi

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth

Hans-Georg Eichler, Francesco Pignatti, Brigitte Schwarzer-Daum, Ana Hidalgo-Simon, Irmgard Eichler, Peter Arlett, Anthony Humphreys, Spiros Vamvakas, Nikolai Brun, Guido Rasi

Summary: Compared to drugs from the past, new drugs are more diverse, including chemicals, biologicals, and cell and gene therapies, mainly for rare diseases and personalized treatments. The changing nature of drugs has implications for definitions, clinical use, and evidence generation. In the future, drug evaluation will involve a combination of randomized controlled trials and real-world evidence for assessing safety and effectiveness.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Editorial Material Medicine, Research & Experimental

The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics

Uttara Soumyanarayanan, Mimi Choong, James Leong, Murray M. Lumpkin, Guido Rasi, John H. Skerritt, Silke Vogel, John C. W. Lim

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Increasing the impact of Post Authorisation Safety Studies: transparency is key

Xavier Kurz, Peter Arlett, Hans-Georg Eichler, Alexis Nolte, Sabine Straus, Guido Rasi

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

News Item Allergy

Legends of allergy and immunology: Sergio Bonini

Giuseppe Maltese, Guido Rasi

ALLERGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Development of a Digital Research Assistant for the Management of Patients' Enrollment in Oncology Clinical Trials within a Research Hospital

Alfredo Cesario, Irene Simone, Ida Paris, Luca Boldrini, Armando Orlandi, Gianluca Franceschini, Filippo Lococo, Emilio Bria, Stefano Magno, Antonino Mule, Angela Santoro, Andrea Damiani, Daniele Bianchi, Daniele Picchi, Guido Rasi, Gennaro Daniele, Alessandra Fabi, Paolo Sergi, Giampaolo Tortora, Riccardo Masetti, Vincenzo Valentini, Marika D'Oria, Giovanni Scambia

Summary: The Digital Research Assistant (DRA) platform provides real-time clinical trial information and support for clinicians. Through the platform, experts can use an AI algorithm to personalize patient recruitment, optimizing the conduct of clinical trials.

JOURNAL OF PERSONALIZED MEDICINE (2021)

添加到收藏夹

Article Microbiology

High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients

Antonella Minutolo, Vita Petrone, Marialaura Fanelli, Marco Iannetta, Martina Giudice, Ines Ait Belkacem, Marta Zordan, Pietro Vitale, Guido Rasi, Paola Sinibaldi-Vallebona, Loredana Sarmati, Massimo Andreoni, Fabrice Malergue, Emanuela Balestrieri, Sandro Grelli, Claudia Matteucci

Summary: CD169 is found to be overexpressed in the blood of COVID-19 patients, and is identified as a biomarker. The high CD169 RMFI in COVID-19 patients is associated with CD8 T-cell senescence and exhaustion markers, as well as with B-cell maturation and differentiation. CD169 is induced by the spike protein of SARS-CoV-2 and can be considered as an early biomarker for evaluating immune dysfunction and respiratory outcomes in COVID-19 patients.

PATHOGENS (2021)

添加到收藏夹

Article Health Care Sciences & Services

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements

Hans-Georg Eichler, Roisin Adams, Einar Andreassen, Peter Arlett, Marc van de Casteele, Suzannah J. Chapman, Wim G. Goettsch, Jonathan Lind Martinsson, Jordi Llinares-Garcia, Anna Nachtnebel, Elias Pean, Guido Rasi, Tove Ragna Reksten, Lonneke Timmers, Rick A. Vreman, Inneke van de Vijver, Martin Wenzl

Summary: The study examined the potential improvement of feasibility of PB-MEAs by aligning regulatory post-authorization requirements and active collaboration. Reviewers found that regulatory post-authorization studies could partly help implement PB-MEAs, but recognized obstacles such as insufficient public information and complexities in implementation. Despite PB-MEAs not being the preferred option for CAPRs, there was seen as potential for their implementation or collaboration across CAPRs.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.